<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144599</url>
  </required_header>
  <id_info>
    <org_study_id>MRA316JP</org_study_id>
    <nct_id>NCT00144599</nct_id>
  </id_info>
  <brief_title>Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)</brief_title>
  <official_title>A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, Phase III study to evaluate the efficacy, safety and PK of MRA in
      patients with sJIA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy:Percentage of patients showing 30% improvement in the JIA core set, Percentage of patients showing improvement in CRP on LOBS</measure>
    <time_frame>open-label period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy:Percentage of patients in whom effects were maintained</measure>
    <time_frame>Blind period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety:Incidence and severity of adverse events and adverse drug reactions</measure>
    <time_frame>whole period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics:The time course of the trough serum MRA concentration</measure>
    <time_frame>whole period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy:Time courses of CRP and ESR, percentage of patients showing 30%, 50%, and 70% improvement in the JIA core set, JIA core set variables, pain, maximum body temperature, systemic feature score</measure>
    <time_frame>Open-label period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period for which effects, Time course of CRP and ESR, percentage of patients showing 30%, 50%, and 70% improvement in the JIA core set,JIA core set variables,pain, maximum body temperature,systemic feature score up to LOBS</measure>
    <time_frame>Blind Period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Systemic Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRA(Tocilizumab)</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Patients diagnosed as having systemic JIA based on the International League of
             Associations for Rheumatology criteria (1997)

          -  Patients between 2 and 19 years of age

          -  Patients who are under 16 years of age at onset

          -  Patients who have been treated with corticosteroids (continued treatment for 3 months
             or longer at a dose of â‰¥0.2 mg/kg as prednisolone equivalent) but who failed to
             respond adequately or in whom treatment could not be continued or the dose could not
             be increased due to adverse drug reactions

        Exclusion criteria

          -  Patients who have been treated with infliximab or etanercept within 12 weeks before
             treatment with the investigational product

          -  Patients who have received the following treatments within 4 weeks before treatment
             with the investigational product

               1. Surgical treatment (e.g., operation)

               2. Plasma exchange therapy&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takahiro Kakehi</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>July 29, 2008</last_update_submitted>
  <last_update_submitted_qc>July 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical</name_title>
    <organization>Chugai Pharmaceutical</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

